Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03845400 · ClinicalTrials.gov registry record
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America
A clinical trial, sponsored by Shire.
- Completed
- Registry status
- 168
- Enrollment target
NCT03845400 is a clinical trial that has completed, run by Shire. The registered enrollment target is 168 participants.
The verdict
NCT03845400 has completed, sponsored by Shire.
- COMPLETED
- Registry status
- 168 participants
- Enrollment target
Study Summary
The main aim of this study is to compare the HAE attack rate before and after lanadelumab treatment was started in persons with Hereditary Angioedeme Type I or II. Data from participants will be collected for at least 24 months. Participants will report information in a smartphone application at study start and then every 3 months until the study ends; data will also be collected by the study doctor during routine clinic visits.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2019-03-30 |
| Est. Completion | 2022-10-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03845400
The ClinicalTrials.gov registry entry for NCT03845400 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03845400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03845400 about?
NCT03845400 is a clinical study titled "A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America". The main aim of this study is to compare the HAE attack rate before and after lanadelumab treatment was started in persons with Hereditary Angioedeme Type I or II. Data from participants will be collected for at least 24 months. Participants will report information in a smartphone application at st...
What is the current status of trial NCT03845400?
This trial is currently completed. The enrollment target is 168 participants. The study started on 2019-03-30. Estimated completion is 2022-10-22.
Who is sponsoring clinical trial NCT03845400?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.